The T-SPOT.COVID test antigen mix optimized for SARS-CoV-21
The T-SPOT.COVID test is a simple blood test intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, specifically the T cell response. The test uses the T-SPOT Technology, a modified ELISPOT technology, with an optimised antigen mix, based on SARS-CoV-2 structural proteins, spike and nucleocapsid (S and N), and allows the maximum breadth of the immune response to be measured.
The T-SPOT.COVID test1
CE marked for IVD use
Proven to detect evidence of a T cell-mediated immune response to SARS-CoV-2 infection in PCR positive patients with a negative serology test result
Results, complemented by serology results, give a comprehensive view of an individuals’ immune response to SARS-CoV-2
Results can be generated quickly, the laboratory process takes just 2 days
Why partner with Oxford Immunotec?
A leading global diagnostics company with an 18-year history of transforming T cell science into meaningful insights using the T-SPOT Technology. The T-SPOT Technology is proven in TB diagnostics with > 20 million tests shipped to > 50 countries where the T-SPOT.TB test is approved for clinical use.
_Why offer COVID-19 T cell testing?_
Performance of the T-SPOT.COVID test
Time after positive PCR results
T-SPOT.COVID positive agreement
T-SPOT.COVID negative agreement
< 60 days
> 60 days
Positive agreement: 135 individuals with a previous positive COVID-19 test result
Negative agreement: 98 individuals at low risk of acquiring infection and who have never had a positive COVID-19 test result
Higher positive agreement than a leading serology test1
In a study of 135 individuals, with a previous positive PCR result for SARS-CoV-2 infection, samples were analysed by both the T-SPOT.COVID test and a leading serology test.
T cell positive agreement remained high throughout the length of the study
Serology positive agreement decreased over time
Serology positive agreement was low before 14 days
Serology alone is not enough1
Research shows T cell response and antibody immune response are independently correlated to protection against SARS-CoV-2. Antibody response represents half of the immune system and T cells are the other half.
Further analysis of the study cohort evaluated overlap between the two test methods.
The T-SPOT.COVID test identified 51% more PCR positive individuals than serology testing alone
How does the T-SPOT technology work? Our T-SPOT.COVID test based on ELISPOT technology is normalised for both cell number and culture conditions. This means that the test standardises the number of cells and removes serum factors that could adversely affect results, making it the most sensitive and specific test for T cell measurement. A blood sample is collected using routine phlebotomy and a standard blood collection tube from which a subset of white blood cells, known as peripheral blood mononuclear cells (PBMCs), are isolated. The cells are washed, counted and normalised to create a standard cell suspension. A standard number of cells are added into specially designed plates and stimulated with antigens specific to the disease under study. Cells responding to these antigens release a chemical messenger known as a cytokine. Cytokine antibodies are used to directly capture the cytokine as it is released by the cells. A secondary labelled antibody is added and binds to the captured cytokine. A detection reagent is added and reacts with the secondary labelled antibody. This reaction produces spots, which are a footprint of where the cytokine was released. Spots are then enumerated.
What does a positive T-SPOT.COVID test result mean? A positive test result means that the patient has T cells that are reactive to the SARS-CoV-2 specific peptides used in the T-SPOT.COVID test. It is highly likely that they have been exposed to the SARS-CoV-2 virus.
What does a negative test result mean? A negative test result means that the patient does not have T cells that are reactive to the SARS-CoV-2 specific peptides used in the test. It is therefore unlikely that they have been exposed to the SARS-CoV-2 virus.
What regulatory approval does the T-SPOT.COVID test have? The T-SPOT.COVID test is CE marked and has been submitted to the FDA for Emergency use authorisation.
A prospective cohort study performed by Public Health England used the T-SPOT research use only platform to provide detailed information on SARS-CoV-2-specific T cells in immune responses to SARS-CoV-2 infection. In this study, 2,826 individuals identified as keyworkers were tested for anti-spike IgG and SARS-CoV-2 responsive T cells.
T cell responses could be detected in individuals who had tested positive for SARS-CoV-2 using PCR, but were seronegative
T cells may play a role in protection against re-infection with the SARS-CoV-2 virus, even in the absence of detectible antibody
Check Oxford Immunotec’s knowledge hub, where you will find insightful and up to date resources for you, the healthcare professional, connecting the dots between TB and COVID-19 and highlighting the importance of TB testing in a COVID-19 environment.
Wyllie D, Mulchandani R, Jones HE et al. SARS-CoV-2 Reactive T cell numbers are associated with protection from COVID-19: A prospective cohort study. medRxiv. doi: 10.11012020.11.02.20222778
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.